COMMUNIQUÉS West-GlobeNewswire

Seer Announces CFO Transition
21/09/2026
REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the [...]
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
21/09/2026
The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that [...]
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
21/09/2026
BOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Underarm Pad Surface Area and Handle Angle: The Measurements Behind Crutch Comfort
21/09/2026
Drive Medical builds the MD by Drive Air-Crutch handle angle and grip size around load calculations run at the handgrip by Max Younger, who designed the crutch and now leads the line. The Airgonomic™ underarm cushion [...]
Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
21/09/2026
CagriSema 1.0 mg/1.0 mg achieved superior weight loss of 12.4%* versus tirzepatide 5 mg of 9.1%* and non-inferior HbA 1c reduction at week 60 in adults with type 2 diabetes in REIMAGINE 5. CagriSema 1.0 mg/1.0 mg [...]
ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy
21/09/2026
ALK today announced the appointment of Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy (CPPS), effective 1 October 2026. Tina succeeds Jacob Glenting, who headed CPPS before [...]
Highlights to be presented at Novo’s Capital Markets Day 2026
21/09/2026
Bagsværd, Denmark, 21 September 2026 – Novo Nordisk is today hosting a Capital Markets Day (CMD) in London, where the company is providing an update to its Corporate strategy and strategic ambitions for 2030 1 . During [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
21/09/2026
COPENHAGEN, Denmark, September 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Beacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
21/09/2026
VISTA met its FDA-endorsed primary endpoint, demonstrating statistically significant low luminance visual acuity (LLVA) responder rates at Month 12 compared to the untreated control group A statistically significant [...]
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
21/09/2026
Transformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, [...]
SodaPeak Launch 2026: Effective Formula For Men Health Supports Men's Virility and vitality. Read Soda Peak Gummies Supplement Facts & Ingredients Highlights.
20/09/2026
Soda Peak Gummies introduces a natural vitality formula for men, featuring SodaPeak with selected botanical ingredients, supplement facts, and a multi-ingredient blend designed for everyday men’s wellness and vitality [...]
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
20/09/2026
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Primary endpoint and the key secondary endpoint were met [...]
NorahLux Launches Red Light Therapy Research Hub With Access to 10,000+ Photobiomodulation Studies
20/09/2026
Interactive research explorer helps users search scientific literature by condition, study type, light source and other criteria DEURNE, Netherlands, Sept. 19, 2026 (GLOBE NEWSWIRE) -- NorahLux has launched the Red [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
18/09/2026
SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel [...]
Johns Hopkins USFHP is One of the Highest-Rated Health Plans in the Nation
18/09/2026
TRICARE Prime® Option Earns 4.5/5 in NCQA’s 2026 Ratings HANOVER, Md., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Johns Hopkins US Family Health Plan (USFHP) was recognized with an overall rating of 4.5 out of 5 in the National [...]
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
18/09/2026
New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tardive dyskinesia (TD [...]
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
18/09/2026
New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I) The new real-world data also show that [...]
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
18/09/2026
In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of participants [...]
NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update
18/09/2026
CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in Boston TORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) -- [...]

Pages

Other news

Promaxo Announces Closing of Series C Financing and $100M Credit Facility

Contenu:

The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

Contenu:

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp.

BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness

Contenu:

BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine.

New York, Oct. 22, 2026 (GLOBE NEWSWIRE) --

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Contenu:

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

Contenu:

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Contenu:

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Contenu:

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc.